OPEN ACCESS

PGC-1 α limits angiotensin II-induced rat vascular smooth muscle cells proliferation via attenuating NOX1-mediated generation of reactive oxygen species

Qingbin Zhao*1, Junfang Zhang† and Huifang Wang*

*Department of Geratology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi 710061, China †Department of Internal Medicine, Chencang Hospital, Baoji, Shanxi 721300, China

Synopsis

Angll (angiotensin II)-induced excessive ROS (reactive oxygen species) generation and proliferation of VSMCs (vascular smooth muscle cells) is a critical contributor to the pathogenesis of atherosclerosis. PGC-1 α [PPAR γ (peroxisome-proliferator-activated receptor γ) co-activator-1 α] is involved in the regulation of ROS generation, VSMC proliferation and energy metabolism. The aim of the present study was to investigate whether PGC-1 α mediates AnglI-induced ROS generation and VSMC hyperplasia. Our results showed that the protein content of PGC-1 α was negatively correlated with an increase in cell proliferation and migration induced by AnglI. Overexpression of PGC-1 α inhibited AnglI-induced proliferation and migration, ROS generation and NADPH oxidase activity in VSMCs. Conversely, Ad-shPGC-1 α (adenovirus-mediated PGC-1 α -specific shRNA) led to the opposite effects. Furthermore, the stimulatory effect of Ad-shPGC-1 α on VSMC proliferation was significantly attenuated by antioxidant and NADPH oxidase inhibitors. Analysis of several key subunits of NADPH oxidase (Rac1, p22^{phox}, p40^{phox}, p47^{phox} and p67^{phox}) and mitochondrial ROS revealed that these mechanisms were not responsible for the observed effects of PGC-1 α . However, we found that overexpression of PGC-1 α on NADPH oxidase activity. Our data support a critical role for PGC-1 α in the regulation of proliferation and migration do NOX1 (NADPH oxidase 1) expression. These alterations underlie the inhibitory effect of PGC-1 α on NADPH oxidase activity. Our data support a critical role for PGC-1 α in the regulation of proliferation and migration of VSMCs, and provide a useful strategy to protect vessels against atherosclerosis.

Key words: angiotensin II, NADPH, NOX1, PGC-1a, proliferation, reactive oxygen species.

Cite this article as: Bioscience Reports (2015) VV(I) 35, e00252, doi:10.1042/BSR20150112

INTRODUCTION

During the progression and development of atherosclerosis, VS-MCs (vascular smooth muscle cells) proliferates and migrates to the bulk of extracellular matrix, resulting in the thickening of the artery wall and exacerbating atherosclerotic lesions [1,2]. VSMC hyperplasia caused by abnormal proliferation and migration is a major contributor to the development of atherosclerosis [3]. Increasing evidence has shown that AngII (angiotensin II) plays an important role during proliferation in VSMCs [4,5]. AngII activates diverse signalling responses via binding the AT₁R (AngII type 1 receptor), consequently mediating ROS (reactive oxygen species), proliferation and migration [6–8]. However, the mech-

anisms by which AngII induces the excessive proliferation of VSMC have not been fully elucidated.

NADPH oxidase is a principal factor in AngII-induced ROS generation [9], which is an essential contributor to cell proliferation and atherosclerosis [10]. The NADPH oxidase comprises the several main isoforms of ROS-generating enzymes: two plasma membrane subunits NOX2 (NADPH oxidase 2)/gp91^{phox} and p22^{phox}, and four cytosolic subunits p40^{phox}, p47^{phox}, p67^{phox} and Rac1 [11]. These subunits differ not only in their capacity to generate ROS, but also in their distribution in specific cell types. Notably, VSMCs lack NOX2, but express the NOX2 homologue NOX1 [12,13]. However, whether NOX1 is involved in the regulation of VSMC proliferation remains unknown.

Abbreviations: Ad-NOX1, adenovirus-mediated NOX1-specific siRNA; Ad-PGC-1*α*, adenovirus-mediated PGC-1*α*-specific siRNA; Ad/shPGC-1*α*, adenovirus-mediated PGC-1*α*-specific shRNA; AngII, angiotensin II; CHX, cycloheximide; DMEM, Dulbecco's modified Eagle's medium; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; H₂DCFDA, 2',7'-dichlorofluorescin diacetate; MOI, multiplicity of infection; mROS, mitochondrial ROS; NAC, *N*-acetyl-L-cysteine; NOX, NADPH oxidase; PGC-1*α*, PPAR_Y (peroxisome-proliferator-activated receptor *γ*) co-activator-1*α*; RLU, relative light unit(s); ROS, reactive oxygen species; VSMC, vascular smooth muscle cell.

 1 To whom correspondence should be addressed (email zhaoqingbin05@126.com).

PGC-1 α [PPAR γ (peroxisome-proliferator-activated receptor γ) co-activator-1 α] is considered to be the main regulator of the expression of many mitochondrial proteins and energy metabolism [14,15]. PGC-1 α regulates cell differentiation [16], gluco-neogenesis [17], neuron excitability and ROS generation [18]. Interestingly, it has been documented to be a broad and powerful regulator of ROS metabolism, because reduction in PGC-1 α paralleled with a decrease in antioxidant enzymes [18]. Moreover, a study in VSMCs by overexpression and knockdown strategies demonstrated that PGC-1 α inhibited high-glucose-induced VSMC proliferation [19].

In the present study, we therefore sought to determine whether PGC-1 α plays a vital role in AngII-induced ROS-mediated VSMC proliferation and migration, and to explore further the potential mechanisms.

MATERIALS AND METHODS

Materials and reagents

DMEM (Dulbecco's modified Eagle's medium)/Ham's F12, FBS and MitoSOX Red reagent were purchased from Invitrogen. AngII, Crystal Violet, NAC (*N*-acetyl-L-cysteine), antimycin A, ML171 (2-acetylphenothiazine), lucigenin, NADPH and CHX (cycloheximide) were purchased from Sigma Chemical Co. Chloroquine, MG132 and protease and phosphatase inhibitor cocktail were from Calbiochem. Anti-p- $p47^{phox}$ (Ser³⁷⁰) antibody was obtained from Assay Biotechnology. Antibodies targeting $p47^{phox}$ and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) were purchased from Cell Signaling Technology. Antibodies against PGC-1 α , total Rac1 and $p22^{phox}$ were from Santa Cruz Biotechnology. Antibodies targeting $p40^{phox}$, $p67^{phox}$ and NOX1 were obtained from Abcam.

Male Sprague–Dawley rats 3–4 weeks of age were supplied by the Experimental Animal Center of Xi'an Jiaotong University, Xi'an, Shanxi, China. All animal experiments were approved by the Committee on the Ethics of Animal Experiments of Xi'an Jiaotong University.

Cell culture

Primary VSMCs were isolated from rat thoracic aortas as described previously [19]. The cells were maintained in DMEM/Ham's F12 supplemented with 20% (v/v) FBS at 37° C in a humidified incubator supplemented with 5% CO₂. All experiments were conducted using VSMCs between passages 4 and 8 that were growth-arrested at 70% confluence for 48 h with medium containing 0.1% FBS.

[³H]thymidine-incorporation assay

VSMCs were seeded in 24-well plates and growth-arrested by incubating in DMEM/Ham's F12 containing 0.1% FBS for 48 h. The quiescent cells were divided into several groups and

applied to different treatments, then $1 \mu \text{Ci/ml} [^3\text{H}]$ thymidine was added for 3 h of incubation at 37°C. The incorporation of [³H]thymidine into DNA was examined with Beckman liquid-scintillation counter.

Cell migration assay

The cell migration assay was performed using Transwell chambers with fibronectin-coated 8- μ m-pore-size polycarbonate membrane (BD Bioscience). VSMCs subjected to adenovirus infection in the absence or presence of AngII according to the experiment requirements were suspended in DMEM/Ham's F12 containing 0.5 % FBS. Then, 600 μ l of serum-free medium was added to the lower compartment and 100 μ l of cell suspension (4×10⁴ cells/well) was added to the upper compartment. The cells were incubated at 37 °C. After 24 h, non-migrated cells on the upper membrane were removed by a cotton swab. The migrated cells were fixed with methanol for 30 min and stained with 0.1 % Crystal Violet. Stained migratory cells were photographed under an inverted light microscope and quantified by manual counting (Olympus Corporation) in five randomly selected areas of view. Six independent experiments were performed.

Pharmacological approaches

NAC (5 mmol/l), ML171 (5 μ mol/l), antimycin A (10 μ mol/l), rotenone (20 μ mol/l), chloroquine (10 μ g/ml) or MG132 (10 μ g/ml) was added to the cell culture for 1 h before various treatments. For experiments using ML171, chloroquine or MG132, the compound was continued during the stimulation, whereas for other treatments, medium containing the compound was replaced by fresh medium according to the experimental requirements. AngII (0.1 μ mol/l) or CHX (10 μ g/ml) was added to cells for the indicated time.

Western blot analysis

VSMCs were lysed in RIPA lysis buffer (Beyotime) containing protease and phosphatase inhibitor cocktail. Protein concentration was determined by Bradford assay (Bio-Rad Laboratories). Equal amounts of protein were separated by SDS/PAGE (6–10% gel) and transferred on to nitrocellulose membranes (Millipore). The membranes were blocked in 5% (w/v) non-fat dried skimmed milk powder in TBS, followed by incubation of the appropriate primary antibodies. After washing with TBS, membranes were incubated with secondary antibodies including HRP (horseradish peroxidase)-conjugated anti-rabbit, anti-mouse or anti-goat antibodies (Cell Signaling Technology), and the bands were visualized using an ECL kit (Beyotime).

Adenovirus infection of rat VSMCs

Ad-shPGC-1 α (adenovirus-mediated PGC-1 α -specific shRNA), Ad-PGC-1 α (adenovirus-mediated PGC-1 α -specific siRNA) and Ad-NOX1 (adenovirus-mediated NOX1-specific siRNA) were purchased from Sunbio Medical Biotechnology. Adenovirus infection of the quiescent VSMCs was performed at different MOIs (multiplicities of infection) in DMEM/Ham's F12 containing 2% (v/v) FBS for 48 h and treated with AngII according to the experiment requirements. LacZ (Clotech) was used as a negative control.

ROS detection

ROS in VSMCs were visualized by H₂DCF-DA (2',7'dichlorofluorescin diacetate) (Invitrogen) as described previously [18]. VSMCs were seeded in six-well plates or 96-well blackbottomed plates, and then different treatments were applied. After treatment, cells were incubated with H₂DCF-DA (10 μ mol/l) in serum-free DMEM/Ham's F12 for 30 min at 37 °C. Then cells were washed twice with PBS and images were taken with a confocal laser-scanning microscope (FV1000, Olympus) at 488 nm excitation and 525 nm emission wavelengths. To quantify the fluorescence intensity of H₂DCF-DA, stained cells in 96-well plates were quantified using an Infinite F500 Microplate Reader at the same excitation and emission wavelengths and normalized to protein concentrations.

Detection of mROS (mitochondrial ROS) generation

MitoSOX Red reagent, which is a highly selective mitochondrial dye, was used to measure mROS. In brief, cells were incubated with MitoSOX Red (5 μ mol/l) in serum-free DMEM/Ham's F12 in the dark at 37 °C for 30 min. Finally, the cells were gently washed with warm PBS and visualized under an Olympus fluorescence microscope.

Detection of NADPH oxidase activity

NADPH oxidase activity of VSMCs was measured by a lucigenin ECL assay as described previously [20]. Briefly, VSMCs were washed twice with PBS and lysed in NADPH lysis buffer (1.0 mol/l K₂HPO₄, 0.1 mol/l EGTA, 0.15 mol/l and protease inhibitor cocktail, pH 7.0) and sonicated with three cycles of 6-s bursts on ice. After centrifugation at 12000 *g* for 5 min, the supernatant was harvested and incubated with lucigenin (5 mmol/l) for 10 min at 37 °C in the dark. The basal RLU (relative light units) of chemiluminescence were determined using a luminometer (Promega). NADPH (100 μ mol/l) was immediately added to the suspension to start the reaction and the chemiluminescence was determined as experimental RLU. The NADPH oxidase activity was expressed as RLU, which were normalized to protein concentration.

RNA isolation and analysis

Total RNA from VSMCs was isolated using an RNeasy Micro Kit (Qiagen) according to the manufacturer's instructions. Reverse transcription was performed using the ReverTra ACE qPCR RT Kit (Toyobo) and PCR amplification was carried out with the ABI Prism 7000 sequence detection (Applied Biosystems). Sequencespecific primers and SYBR Green PCR master mix were obtained from Invitrogen. The primer sequences used to amplify rat *Nox1* cDNA were 5'-TCACTAACGTGTGGGTCAGC-3' (sense) and 5'-GCTCTCATGTTGCCAAAGCC-3' (antisense); primers for *Nox2* were 5'-TTGGCTGGCATCACAGGAAT-3' (sense) and 5'-TCAAACTGTCCGAAGTCTGTCC-3' (antisense); primers for *Nox4* were 5'-CCTCTGTCTGCTTGTTTGGC-3' (sense) and 5'-TCCTAGGCCCAACATCTGGT-3' (antisense); primers for *Actb* (β -actin) were 5'-AGGGAAATCGTCGTGGCGTGAG-3' (sense) and 5'-CGCTCATTGCCGATAGT-3' (antisense). Amplification was carried out for 38 cycles of 95 °C for 30 s, 60 °C for 1 min and 72 °C for 30 s after an initial 5 min at 95 °C.

Rac1 activation assay

The activity of Rac1 was determined using Rac1 activation assay kit (Cell Biolabs) according to the manufacturer's instructions. Proteins were incubated with beads conjugated to PAK (p21-activated protein kinase) PBD (p21-binding domain) for 1 h at 4° C. Beads were boiled in SDS buffer to release active Rac1. The activated Rac1 was detected by Western blotting using a specific anti-Rac1 antibody.

Statistical analysis

All data are given as means \pm S.E.M. and analysed by SPSS 17.0 statistical software. For the dosing of AngII, a one-way AN-OVA was used. A two-way or three-way ANOVA was used for two-factor or three-factor analysis. The regression analysis was determined using the Pearson correlation test. Values of P < 0.05 were considered to be statistically significant.

RESULTS

AnglI-induced VSMC proliferation and migration are negatively correlated with PGC-1 α expression

Rat VSMCs were treated with various concentrations of AngII $(10^{-9}-10^{-6} \text{ mol/l})$ for 48 h. We found that AngII increased cell proliferation and migration in a dose-dependent manner. AngII at 0.1 μ mol/l resulted in a nearly 3.4-fold increase in proliferation and a 1.9-fold increase in migration respectively compared with the control group (Figures 1A and 1B).

To clarify the relationship between AngII-induced VSMC proliferation and PGC-1 α expression, we investigated the effects of different concentrations of AngII on PGC-1 α expression in rat VSMCs. As shown in Figure 1(C), incubation of AngII for 48 h decreased PGC-1 α protein expression in a dose-dependent manner. PGC-1 α expression reached the minimal expression level at 0.1 μ mol/l. Therefore 0.1 μ mol/l AngII was used in the subsequent experiments. Moreover, the regression analysis showed that PGC-1 α expression was negatively correlated with the cell proliferation and migration respectively (Figures 1D and 1E), suggesting that PGC-1 α expression may be involved in AngIIinduced VSMC proliferation and migration.




Figure 1 AnglI-induced VSMC proliferation and migration is associated with decreased PGC-1 α expression (A) The quiescent rat VSMCs were incubated with different concentrations of AnglI ($10^{-9}-10^{-6}$ mol/I) for 48 h. Cells were incubated with [³H]thymidine for the last 3 h. Incorporation of [³H]thymidine was then determined. (B) Quantification of cell migration after AnglI challenge. (C) Western blot analysis of PGC-1 α protein expression. Molecular masses are indicated in kDa. (D and E) The incorporation of [³H]thymidine (D) and cell migration (E) were negatively correlated with the expression of PGC-1 α respectively. **P < 0.01 compared with control (n = 6).

$\text{PGC-1}\alpha$ inhibits AnglI-induced VSMC proliferation and migration

To investigate further the role of PGC-1 in VSMC proliferation and migration, cells were infected with Ad-shPGC-1 α for 48 h. The silencing efficiency was evaluated by Western blotting. PGC- 1α protein level showed a 69% decrease after Ad-shPGC- 1α infection at 40 MOI compared with the control group. Conversely, PGC-1 α protein expression was significantly elevated following overexpression of PGC-1 α using Ad-PGC-1 α . The maximal expression level of PGC-1 α was observed at 20 MOI, whereas LacZ showed no effect (Figure 2A). Therefore we selected AdshPGC-1 α at 40 MOI and Ad-PGC-1 α at 20 MOI for 48 h in the subsequent experiments. [³H]thymidine incorporation in VS-MCs infected with Ad-PGC-1 α or Ad-shPGC-1 α was comparable with that in untreated cells (results not shown). Strikingly, the ability of AngII to induce cell proliferation was almost lost when VSMCs were infected with Ad-PGC-1a. However, PGC- 1α knockdown dramatically enhanced AngII-induced VSMC proliferation (Figure 2B). Similarly, Transwell analysis showed that the increased number of migrated cells induced by AngII was decreased after PGC-1 α overexpression, whereas conditions with PGC-1 α knockdown demonstrated the opposite (Figures 2C and 2D). Of note, the enhanced effects of PGC-1 α inhibition on AngII-induced cell proliferation and migration were all markedly attenuated by the antioxidant NAC (5 μ mol/l).

PGC-1 α limits AnglI-induced ROS generation via inhibition of NOX1

We first evaluated the effect of PGC-1 α on total ROS generation with the ROS-reactive dye H₂DCF-DA. Overexpression or inhibition of PGC-1 α produced no effect on ROS generation in the absence of AngII (results not shown). AngII treatment significantly increased ROS generation, which was almost abolished by PGC-1 α overexpression. In contrast, PGC-1 α knockdown further enhanced AngII-induced ROS generation (Figures 3A and 3B). These data indicate the essential role of PGC-1 α in the regulation of AngII-induced ROS generation in VSMCs.

Next, we examined how PGC-1 α regulates AngII-induced ROS generation in VSMCs. Incubation of VSMCs with mROS-specific stimulators, such as antimycin A and rotenone, did not ablate the inhibitory effect of PGC-1 α on ROS generation induced by AngII (Figures 3A and 3B). Although MitoSOX Red fluorescence was higher following AngII exposure, no significant differences were noted across treatment conditions (Figures 3C and 3D). These data exclude the possibility that PGC-1 α knockdown accelerates AngII-induced ROS generation via increasing mROS generation. Interestingly, pharmacological inhibition of NOX1 with its selective inhibitor ML171 largely abrogated the elevation of ROS generation in Ad-shPGC-1 α -infected AngII-treated cells (Figures 3A and 3B). In addition to NAC, we found that ML171 also remarkably prevented the excessive




Figure 2 Effects of PGC-1α on AnglI-induced VSMC proliferation and migration


(A) VSMCs were transfected with LacZ (80 MOI), Ad-shPGC-1 α (20, 40 and 80 MOI) or Ad-PGC-1 α (10, 20 and 40 MOI) for 48 h. Efficiency of infection was confirmed by Western blotting with anti-PGC-1 α antibody. Molecular masses are indicated in kDa. (B) Cells were pre-treated with NAC (5 mmol/l) for 1 h, followed by transfection of LacZ (40 MOI), Ad-shPGC-1 α (40 MOI) or Ad-PGC-1 α (20 MOI) for 48 h, and then were submitted to AnglI (0.1 μ mol/l) conditions for another 48 h. [³H]thymidine was added and the incorporation of [³H]thymidine was determined at 3 h. (C) VSMC migration was examined by Transwell analysis after the treatment in (B). Representative images for cell migration assay captured by microscope from six independent experiments (×200 magnification). (D) Quantitative analysis of cell migration. **P < 0.01 compared with AnglI; &&P < 0.01 compared with AnglI; &&P < 0.01 compared with AnglI; #P < 0.01 compared with AnglI; *P < 0.01 compared with A

proliferation in Ad-shPGC-1 α -infected AngII-treated cells (Figure 3E). Collectively, these data suggest that NOX1 activation may underlie, at least in part, the enhanced effect of PGC-1 α knockdown on ROS generation and cell proliferation.

PGC-1 α attenuates AnglI-stimulated NADPH oxidase activity through specifically inhibiting NOX1 expression

Because NOX1 is an important isoform of NADPH oxidase, we investigated whether PGC-1 α influences NADPH oxidase activity directly. As shown in Figure 4(A), overexpression of PGC-1 α remarkably attenuated the AngII-induced increase in NADPH oxidase activity, whereas blockade of PGC-1 α produced the opposite effects. Notably, inhibition of NOX1 with ML171 almost abolished the enhanced effects of PGC-1 α knockdown on NADPH oxidase activity. To confirm whether the effects of PGC-1 α on NADPH oxidase activity are associated with NOX1, we co-infected VSMCs with Ad-PGC-1 α and Ad-NOX1 in the presence of AngII. The successful overexpression of NOX1 expression was confirmed by Western blot analysis and quantitative PCR (Supplementary Figures S1A and S1B). Moreover, overexpression of NOX1 in rat VSMCs did not alter the expression of NOX2 and NOX4 (Supplementary Figure S1B). Following overexpression of NOX1, the inhibitory effect of PGC-1 α on NADPH oxidase activity under AngII stimulation was abolished, indicating that NOX1 is a critical molecular target for PGC-1 α in the regulation of NADPH oxidase activity.

The NADPH oxidase complex in VSMCs is composed of two membrane subunits, NOX2/gp91^{*phox*} and p22^{*phox*}, and four



(A) Cells were pre-treated with test compounds as described in the Materials and methods section. Then VSMCs were infected with LacZ, Ad-shPGC-1 α or Ad-PGC-1 α for 48 h before incubation with AnglI (0.1 μ mol/I) for another 48 h. Representative images (×200 magnification) for cells loaded with H₂DCF-DA (10 μ mol/I) for 30 min. (B) Quantitative analysis of DCF (2',7' dichlorofluorescein) fluorescence intensity. (C) Confocal microscopy was used to localize mROS generation (×200 magnification). (D) Quantitative analysis of MitoSOX fluorescence intensity. (E) VSMCs were pre-treated with ML171 (5 μ mol/I) for 1 h, and were then infected with LacZ or Ad-shPGC-1 α before exposure to AnglI (0.1 μ mol/I) for 48 h. [³H]thymidine was added and the incorporation of [³H]thymidine was determined after 3 h. **P < 0.01 compared with AnglI; &&P < 0.01 compared with Ad-shPGC-1 α +AnglI (n = 6).

cytosolic subunits, p40^{phox}, p47^{phox}, p67^{phox} and Rac1 [11,12]. To determine whether PGC-1 α regulates NOX1 specifically, the activation or expression of these subunits was measured. In PGC-1 α -knockdown VSMCs, the phosphorylation of p47^{phox} and activation of Rac1 were comparable with those of LacZ-infected cells under AngII stimulation (Figures 4B and 4C). The expression of Rac1, p22^{phox}, p40^{phox} and p67^{phox} remained unchanged across the different treatment conditions. Although p47^{phox} protein expression was elevated following exposure to AngII, few significant changes were observed after overexpression or knockdown of PGC-1 α . Of note, NOX1 expression was strikingly

increased after AngII treatment. Moreover, following PGC-1 α overexpression, NOX1 expression was no longer elevated by AngII. In contrast, the increased NOX1 expression was augmented further in Ad-shPGC-1 α -infected cells (Figures 4D and 4E).

$\label{eq:pgc-1} \mbox{PGC-1} \alpha \mbox{ decreases NOX1 expression induced by} \\ \mbox{AnglI through the proteasome degradation pathway} \\$

To investigate further the mechanism by which PGC-1 α inhibits AngII-induced NOX1 expression, we first determined the expression level of *NOX1* mRNA. Although the *NOX1* mRNA





Figure 4 Overexpression of PGC-1 α inhibits AnglI-induced NOX1 expression

(A) Quantitation analysis of NADPH oxidase activity measured in the presence of lucigenin (5 mmol/l) followed by treating with or without NADPH (100 μ mol/l). (**B** and **C**) VSMCs were treated with LacZ or Ad-PGC-1 α for 48 h, and then AnglI at 0.1 μ mol/l was added for the indicated times. Phospho-p47^{phox} and total p47^{phox} (**B**), and active Rac1 and total Rac1 (**C**) were detected by Western blotting. Molecular masses are indicated in kDa. (**D**) Western blot analysis of Rac1, p22^{phox}, p40^{phox}, p67^{phox} and NOX1 in the lysates of VSMCs. Cells were infected with LacZ, Ad-shPGC-1 α for Ad-PGC-1 α for 48 h before incubation of AngII for another 48 h. GAPDH was used as loading control. Molecular masses are indicated in kDa. (**E**) Densitometric analysis of Rac1, p22^{phox}, p40^{phox}, p67^{phox} and NOX1 was performed. **P < 0.01 compared with AngII; &&P < 0.01 compared with AngII; &P < 0.01 compared with AngII; P < 0.01 compared with AngII; P = 0.01 compared with Ad-PGC-1 $\alpha + AngII$ (n = 6).

level was increased following AngII treatment, we did not detect any differences after overexpression or knockdown of PGC-1 α (Figure 5A). These results suggest that post-transcriptional regulation seems to be taking place. We next examined the stability of NOX1 protein by using a protein synthesis inhibitor, CHX (10 μ g/ml). Under AngII stimulation, CHX treatment showed a time-dependent decrease in NOX1 protein level in VSMCs. Compared with the LacZ group, overexpression of PGC-1 α significantly increased the rate of NOX1 degradation, shortening NOX1 protein half-life by more than 3 h (Figure 5B). These results indicate that PGC-1 α participates in the degradation of NOX1 protein. Previous studies have suggested that the proteasomedependent endoplasmic reticulum-associated degradation pathway and lysosome-associated degradation pathway are involved in NOX1 protein degradation [11,21,22]. Therefore cells were pre-treated with the lysosome blocker chloroquine or the proteasome inhibitor MG132 followed by Ad-PGC-1 α infection in the absence or presence of AngII, and then the NOX1 protein level was analysed by Western blotting. Neither of these pharmacological approaches had an effect on NOX1 expression in the absence of AngII. Notably, the inhibitory effect of Ad-PGC-1 α on NOX1 expression in the presence of AngII was dramatically restored by MG132, but not chloroquine (Figures 5C and 5D). Collectively, these data suggest that PGC-1 α inhibits AngII-stimulated NOX1 expression by enhancing NOX1 degradation through the proteasome degradation pathway.

DISCUSSION

Atherosclerosis is the primary cause of heart disease and stroke, which is characterized by smooth muscle proliferation and thickening of the arterial wall [10,23]. Accumulating evidence suggests that AngII is the most potent stimulator of VSMC



(**C** and **D**) Western blot analysis of NOX1 expression in VSMCs pre-treated with chloroquine (10 μ g/ml) (**C**) or MG132 (10 μ g/ml) (**D**) for 1 h and then infected with LacZ or Ad-PGC-1 α in the absence or presence of Angll. Molecular masses are indicated in kDa. **P < 0.01 compared with LacZ alone; ##P < 0.01 compared with LacZ + Angll; &&P < 0.01 compared with Ad-PGC-1 α + Angll (n = 6).

proliferation [4,7]. Therefore an understanding of the precise molecular mechanism of AngII-induced VSMC proliferation is essential to elucidate the pathological process of atherosclerosis. PGC-1 α is an important regulator in mitochondrial function and energy metabolism. A previous study in HeLa cells showed that inhibition of PGC-1 α may contribute to mitochondrial dysfunction [24]. Overexpression of PGC-1 α attenuated ischaemia/reperfusion-induced cardiac contractility in heart [25], whereas a lack of PGC-1 α in mice contributed to the development of cardiac dysfunction [15]. On the other hand, a decrease in PGC-1 α expression was observed in adipose tissue from insulinresistant subjects [26], as well as in skeletal muscle from Type 2 diabetics [27]. Similarly, both mRNA and protein levels of PGC-1 α were significantly reduced after high glucose challenge [19]. These results suggest that the alterations in PGC-1 α expression are causally associated with the corresponding physiological and pathological processes. In the present study, we were the first, to our knowledge, to demonstrate that AngII decreases PGC-1 α expression in rat VSMCs. We found that PGC-1 α protein expression was inhibited by AngII dose-dependently and negatively correlated with cell proliferation and migration. Furthermore, overexpression of PGC-1 α abolished, whereas knockdown of PGC-1 α enhanced, AngII-induced VSMC proliferation and migration. These data indicate that PGC-1 α may function as a key regulator in VSMC proliferation.

Next, we explored the mechanism by which PGC-1 α regulates VSMC proliferation and migration. Although a number of factors contribute to VSMC hyperplasia, it is likely that oxidative

stress is a major underlying mechanism [28]. In the present study, we found that the stimulatory effect of Ad-shPGC-1 α on proliferation and migration was abolished by the antioxidant NAC, demonstrating that oxidative stress is involved in PGC-1 α mediated VSMC growth and movement. Of note, in addition to energy metabolism, PGC-1 α can induce antioxidant defences and ROS metabolism [18,29]. For example, induction of PGC-1 α increased MnSOD (manganese superoxide dismutase) protein and catalase activity in skeletal muscle, which in turn reduced muscle protein oxidation [30]. Consistent with these studies, we found that the excessive ROS generation induced by AngII was attenuated after overexpression of PGC-1 α . ROS have been suggested to be involved a number of pathological processes, including hypertension and atherosclerosis [28]. Mitochondrial electron transport chain and NADPH oxidase are the main sources of intracellular ROS [31,32]. Interestingly, we found that mROSspecific stimulators did not change the inhibitory effect of PGC- 1α overexpression on ROS generation. These results, together with the mROS generation (MitoSOX staining), demonstrated that mROS generation is not responsible for the increased ROS generation after PGC-1 α inhibition. However, NOX1 inhibitor abolished the stimulatory effect of Ad-shPGC-1a on ROS generation, indicating that NADPH oxidase is the main source of ROS generation during this process. This was confirmed by NADPH oxidase activity analysis.

To explain how PGC-1 α regulates NADPH oxidase activity, we examined the protein content of the main subunits of NADPH oxidase. In the present study, we showed that the effect of PGC- 1α on NADPH oxidase activity was not associated with the protein expression of RAC1, p22^{phox}, p40^{phox}, p47^{phox} or p67^{phox}, as well as the phosphorylation of p47^{phox} or activation of Rac1, suggesting that these subunits may be not the molecular targets for PGC-1 α in the regulation of NADPH oxidase activity. Nevertheless, NOX1 shares 56% similarity with NOX2 and is abundantly expressed in specific cell types, such as VSMCs [13]. In the present study, we found that shRNA-mediated knockdown of PGC-1 α enhanced AngII-induced NOX1 expression, whereas overexpression of PGC-1 α alleviated it. Moreover, the inhibitory effect of PGC-1 α on NADPH oxidase activity was abolished following overexpression of NOX1. These results indicate that changes to NOX1 expression probably specifically account for the effect of PGC-1 α on ROS generation and proliferation.

We found that neither up-regulation nor down-regulation of PGC-1 α changed the mRNA level of PGC-1 α , indicating that transcriptional regulation is not involved. CHX treatment showed that overexpression of PGC-1 α accelerated NOX1 degradation in the presence of AngII, suggesting that degradation of NOX1 protein seems to be taking place. Accumulating evidence has found that isoforms of the NOX family could be degraded quickly via a proteasome-dependent endoplasmic reticulum-associated degradation pathway. However, other mechanisms, such as the lysosome-associated degradation pathway, may occur when NOXs translocate from the endoplasmic reticulum to plasma membranes [11,21,22]. In the present study, we found that treatment with proteasome inhibitor restored Ad-PGC-1 α -decreased NOX1 expression, whereas a lysosome blocker pro-

duced no reversible effect. Together, our data suggest that PGC- 1α promotes NOX1 degradation via the proteasome degradation pathway under AngII stimulation, and consequently attenuates NOX1 expression.

In summary, we have demonstrated the correlation between PGC-1 α expression and VSMC proliferation. Our results reveal that PGC-1 α could decrease ROS generation derived from NADPH oxidase, thus attenuating AngII-induced VSMC hyperplasia. These findings suggest that elevation of PGC-1 α may be a novel strategy to prevent the development of atherosclerosis, and support further investigation of PGC-1 α expression in vascular diseases.

AUTHOR CONTRIBUTION

Qingbin Zhao supervised the study. Qingbin Zhao and Junfang Zhang participated in study design and scientific discussion of the data. Junfang Zhang contributed to the scientific discussion of the data. Huifang Wang contributed to the biochemical analysis of the experiments.

FUNDING

This work was supported by the National Natural Science Foundation of China [grant number 81200098] and Shanxi Province Natural Science Foundation of China [grant number 2014K11-03-04-06].

REFERENCES

- Rudijanto, A. (2007) The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med. Indones. **39**, 86–93 <u>PubMed</u>
- 2 Lacolley, P., Regnault, V., Nicoletti, A., Li, Z. and Michel, J.B. (2012) The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc. Res. 95, 194–204 CrossRef PubMed
- 3 Schwartz, S.M. (1997) Smooth muscle migration in atherosclerosis and restenosis. J. Clin. Invest. **100**, S87–S89 <u>PubMed</u>
- 4 Yaghini, F.A., Song, C.Y., Lavrentyev, E.N., Ghafoor, H.U., Fang, X.R., Estes, A.M., Campbell, W.B. and Malik, K.U. (2010) Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation. Hypertension 55, 1461–1467 <u>CrossRef PubMed</u>
- 5 Ohtsu, H., Suzuki, H., Nakashima, H., Dhobale, S., Frank, G.D., Motley, E.D. and Eguchi, S. (2006) Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension 48, 534–540 CrossRef PubMed
- 6 Nguyen Dinh Cat, A., Montezano, A.C., Burger, D. and Touyz, R.M. (2013) Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid. Redox Signal. **19**, 1110–1120 CrossRef PubMed
- 7 Lemarie, C.A. and Schiffrin, E.L. (2010) The angiotensin II type 2 receptor in cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. **11**, 19–31 CrossRef PubMed
- 8 Mehta, P.K. and Griendling, K.K. (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. Cell Physiol. **292**, C82–C97 <u>CrossRef PubMed</u>

- 9 Ushio-Fukai, M., Zafari, A.M., Fukui, T., Ishizaka, N. and Griendling, K.K. (1996) p22^{phox} is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem. **271**, 23317–23321 <u>CrossRef PubMed</u>
- 10 Lusis, A.J. (2000) Atherosclerosis. Nature **407**, 233–241 CrossRef PubMed
- 11 Noubade, R., Wong, K., Ota, N., Rutz, S., Eidenschenk, C., Valdez, P.A., Ding, J., Peng, I., Sebrell, A., Caplazi, P. et al. (2014) NRROS negatively regulates reactive oxygen species during host defence and autoimmunity. Nature **509**, 235–239 <u>CrossRef PubMed</u>
- 12 Lassegue, B., Sorescu, D., Szocs, K., Yin, Q., Akers, M., Zhang, Y., Grant, S.L., Lambeth, J.D. and Griendling, K.K. (2001) Novel gp91^{phox} homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ. Res. **88**, 888–894 <u>CrossRef PubMed</u>
- 13 Martyn, K.D., Frederick, L.M., von Loehneysen, K., Dinauer, M.C. and Knaus, U.G. (2006) Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell. Signal. **18**, 69–82 <u>CrossRef PubMed</u>
- 14 Valle, I., Alvarez-Barrientos, A., Arza, E., Lamas, S. and Monsalve, M. (2005) PGC-1α regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc. Res. 66, 562–573 <u>CrossRef PubMed</u>
- 15 Lin, J., Handschin, C. and Spiegelman, B.M. (2005) Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 1, 361–370 <u>CrossRef PubMed</u>
- 16 Dubey, R.K., Zhang, H.Y., Reddy, S.R., Boegehold, M.A. and Kotchen, T.A. (1993) Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. **265**, R726–R732 <u>PubMed</u>
- 17 Yoon, J.C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C.R., Granner, D.K. et al. (2001) Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature **413**, 131–138 <u>CrossRef PubMed</u>
- 18 St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J.M., Rhee, J., Jager, S., Handschin, C., Zheng, K., Lin, J., Yang, W. et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell **127**, 397–408 <u>CrossRef PubMed</u>
- 19 Zhu, L., Sun, G., Zhang, H., Zhang, Y., Chen, X., Jiang, X., Jiang, X., Krauss, S., Zhang, J., Xiang, Y. and Zhang, C.Y. (2009) PGC-1 α is a key regulator of glucose-induced proliferation and migration in vascular smooth muscle cells. PLoS One **4**, e4182 <u>CrossRef PubMed</u>
- 20 Bruder-Nascimento, T., Chinnasamy, P., Riascos-Bernal, D.F., Cau, S.B., Callera, G.E., Touyz, R.M., Tostes, R.C. and Sibinga, N.E. (2014) Angiotensin II induces Fat1 expression/activation and vascular smooth muscle cell migration via Nox1-dependent reactive oxygen species generation. J. Mol. Cell. Cardiol. 66, 18–26 <u>CrossRef PubMed</u>

- 21 DeLeo, F.R., Burritt, J.B., Yu, L., Jesaitis, A.J., Dinauer, M.C. and Nauseef, W.M. (2000) Processing and maturation of flavocytochrome b₅₅₈ include incorporation of heme as a prerequisite for heterodimer assembly. J. Biol. Chem. **275**, 13986–13993 <u>CrossRef PubMed</u>
- 22 Parkos, C.A., Dinauer, M.C., Jesaitis, A.J., Orkin, S.H. and Curnutte, J.T. (1989) Absence of both the 91kD and 22kD subunits of human neutrophil cytochrome *b* in two genetic forms of chronic granulomatous disease. Blood **73**, 1416–1420 PubMed
- 23 Jara, L.J., Medina, G., Vera-Lastra, O. and Amigo, M.C. (2006) Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun. Rev. 5, 195–201 <u>CrossRef PubMed</u>
- 24 Kim, H.K., Song, I.S., Lee, S.Y., Jeong, S.H., Lee, S.R., Heo, H.J., Thu, V.T., Kim, N., Ko, K.S., Rhee, B.D. et al. (2014) B7-H4 downregulation induces mitochondrial dysfunction and enhances doxorubicin sensitivity via the cAMP/CREB/PGC1-α signaling pathway in HeLa cells. Pflugers Arch. **466**, 2323–2338 CrossRef PubMed
- 25 Lynn, E.G., Stevens, M.V., Wong, R.P., Carabenciov, D., Jacobson, J., Murphy, E. and Sack, M.N. (2010) Transient upregulation of PGC-1α diminishes cardiac ischemia tolerance via upregulation of ANT1. J. Mol. Cell. Cardiol. **49**, 693–698 <u>CrossRef PubMed</u>
- 26 Hammarstedt, A., Jansson, P.A., Wesslau, C., Yang, X. and Smith, U. (2003) Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem. Biophys. Res. Commun. **301**, 578–582 <u>CrossRef PubMed</u>
- 27 Patti, M.E., Butte, A.J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S., Miyazaki, Y., Kohane, I., Costello, M., Saccone, R. et al. (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl. Acad. Sci. U.S.A. 100, 8466–8471 CrossRef PubMed
- 28 Wilkinson-Berka, J.L., Rana, I., Armani, R. and Agrotis, A. (2013) Reactive oxygen species, Nox and angiotensin II in angiogenesis: implications for retinopathy. Clin. Sci. **124**, 597–615 <u>CrossRef PubMed</u>
- 29 Lu, Z., Xu, X., Hu, X., Fassett, J., Zhu, G., Tao, Y., Li, J., Huang, Y., Zhang, P., Zhao, B. and Chen, Y. (2010) PGC-1α regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid. Redox Signal. **13**, 1011–1022 <u>CrossRef PubMed</u>
- 30 Wenz, T., Rossi, S.G., Rotundo, R.L., Spiegelman, B.M. and Moraes, C.T. (2009) Increased muscle PGC-1α expression protects from sarcopenia and metabolic disease during aging. Proc. Natl. Acad. Sci. U.S.A. **106**, 20405–20410 <u>CrossRef PubMed</u>
- 31 Forstermann, U. (2008) Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat. Clin. Pract. Cardiovasc. Med. 5, 338–349 <u>CrossRef PubMed</u>
- 32 Bedard, K., Lardy, B. and Krause, K.H. (2007) NOX family NADPH oxidases: not just in mammals. Biochimie 89, 1107–1112 <u>CrossRef PubMed</u>

Received 1 May 2015/15 July 2015; accepted 14 August 2015

Accepted Manuscript online 26 August 2015, doi 10.1042/BSR20150112